SharePoint
A- A A+

Cancer Information

Leukaemia

Leukaemia

Leukaemia is cancer of the blood cells. It starts in the bone marrow, where blood cells are made. It causes an uncontrolled production of abnormal white blood cells, called leukaemia cells. These cells do not function normally and over time, they crowd out the normal blood cells and usually lead to anaemia, bleeding and infections.


Most Leukaemia patients do not have any identifiable risk. However, the more common risk factors include: 

  • Preceding history of other haematological diseases such as myelodysplastic syndrome, chronic myeloproliferative diseases etc
  • Prior exposure to chemotherapy and radiation therapy due to treatment for other cancers
  • Genetic abnormalities such as Down syndrome
  • Exposure to intense radiation and certain chemicals

*People who think they may be at risk should discuss this with their doctor.


Leukaemia is usually grouped into either chronic (conditions get worse slowly) or acute (conditions get worse quickly). This can be further sub-grouped into the following:

Acute Leukaemia

Acute Myelogenous Leukaemia (AML)

AML is an aggressive type of leukaemia whereby there are too many immature myeloid cells (myeloid blasts) in the blood and bone marrow. AML is the most common type of leukaemia.

Pre-chemotherapy work-up for AML would include a number of blood tests and heart scan. These are essential to determine the suitability of the patient for intensive chemotherapy. A central venous line will be inserted via a vein on the arm to facilitate delivery of chemotherapy and other intravenous medication. It also spares the patient from repeated venupunctures for the purpose of blood tests. Generally, the treatment consists of one to two cycles of induction chemotherapy followed by consolidation therapy.

The chemotherapy process consists of one to two types of chemotherapeutic agents such as cytarabine, idarubicin or daunorubicin. After induction chemotherapy, reassessment of the bone marrow will be carried out to confirm the remission status. The consolidation therapy can be further broken down into three cycles of chemotherapy (for standard risk or favorable risk patients) or allogeneic stem cell transplant (for high risk patients). Thereafter, the patient will be reviewed regularly in the clinic.

Acute Lymphocytic Leukaemia (ALL)

ALL is a fast-growing type of leukaemia whereby there are too many immature lymphoid cells (lymphoid blasts) in the blood and bone marrow. ALL is the most common type of leukaemia in young children.

The pre-chemotherapy work-up is the same as per AML. Younger adults (below 30 years old) will be offered a paediatric-inspired protocol. Those above 30 years old will be offered the standard adult protocol for ALL (HyperCVAD Protocol). Risk stratification of ALL based on genetic and MRD (residual disease) studies will help determine the high risk group for eventual allogeneic stem cell transplant. Those with standard risk disease will be offered consolidation chemotherapy followed by maintenance therapy. Thereafter, patients will be monitored regularly in the clinic.

Chronic Leukaemia

Chronic Myeloid Leukaemia (CML)

CML is another slow-growing type of leukaemia in which too many myeloid cells are produced. Leukaemic blasts only make up a small percentage of this cancer type and CML mainly affects adults

The pre-treatment work-up for CML is much simpler, comprising mainly of a few blood tests to assess the functionality of the organs. The main therapeutic agent is oral tyrosine kinase inhibitor (TKI) which is a targeted therapy. Almost all patients will respond to this treatment. All patients will undergo bone marrow assessment at 3 months, 6 months and 12 months. The TKI will be continued indefinitely. Patients should be on long term follow-up for continuous monitoring of disease progression.

Chronic Myelomonocytic Leukaemia (CMML)

CMML is a type of leukaemia in which there are too many monocytes (white blood cells) in the blood. There are two types of CMML – type 1 and type 2.

  • Type 1 – Fewer than 5 out of every 100 white blood cells (5%) in your blood are abnormal myeloid cells (blasts)
  • Type 2 – Between 5 out of every 100 white blood cells (5%) nd 20 out of every 100 cells (20%) are abnormal myeloid cells (blasts)

Other forms of Chronic Leukaemia which are considered rare include:

  • Chronic Eosinophilic Leukaemia
  • Chronic Neutorphilic Leukaemia
  • Atypical Chronic Myeloid Leukaemia
  • Mast Cell Leukaemia

The different types of leukaemia will in turn determine the symptoms and ultimately the treatment prescribed.


Patients who have chronic leukaemia may not experience any symptoms and their condition is usually detected from routine blood tests. However, for patients with acute leukaemia and as the conditions worsen for chronic leukaemia patients, symptoms may include:

  • Fever or chills
  • Persistent fatigue or weakness
  • Loss of appetite or weight
  • Swollen lymph nodes, enlarged liver or spleen
  • Easy bleeding or bruising or tiny red spots in your skin (petechiae)
  • Shortness of breath or excessive sweating especially at night
  • Bone pain or tenderness
  • Frequent infections

Most often these symptoms can also be caused by problems other than cancer, only a doctor can tell for sure. For an accurate diagnosis, a doctor should be consulted if the symptoms above occur.


If you experience any of the symptoms mentioned, the doctor will need to run some tests to find out what’s causing the problems. Your doctor may ask about your personal and family medical history.

You may have one or more of the following tests.

Physical Exam

Your doctor checks for swollen lymph nodes, spleen, or liver.

Blood Tests

Your doctor will do a complete blood count to check the number of white blood cells, red blood cells, and platelets. Leukaemia causes a very high level of white blood cells, and may also lead to low levels of platelets and haemoglobin, which is found inside red blood cells. 

Biopsy

If leukaemia cells are found, the next step is to run other tests to determine what type of leukaemia you have or other signs of problem.


There are different treatments available for depending on the type of leukaemia. Other factors include your age, your overall health, and your own preferences. The types of treatment that may be prescribed are as follows.

Chemotherapy

Chemotherapy is the use of drugs to help kill leukaemia cells. Depending on the type of leukaemia, you may receive a single drug or a combination of two or more drugs. The drugs are given into a vein, by mouth or into the cerebrospinal fluid. Once the drugs enter our system, they will spread throughout the body.

Chemotherapy is usually given in cycles. Each treatment cycle is followed by a rest period. You may have your treatment in a clinic, at the doctor’s office. Some patient may need to stay in hospital for treatment.

Targeted Therapy

Targeted therapy is the use of drugs to block the growth of leukaemia cells, through the interference of specific targeted molecules. The drugs can be used to stop cancer cells progression, cause cancer cells death and even stimulate the immune system to recognise and destroy cancer cells, while sparing the normal cells.

Only certain subtypes of leukaemia will benefit from targeted therapy. This will depend on the findings of the genetic study.

Biological Therapy

Biological therapy is the use of substances that bolster one’s immune response to leukaemia. This can be administered through the vein or injected under the skin into a muscle. The drugs can either slow the growth of the leukaemia cells or helps the immune system destroy the cells.

Radiation Therapy

Radiation therapy is a cancer treatment that uses high energy x-rays or other types of radiation to kill leukaemia cells or keep them from growing. In this case, radiation will be targeted at the spleen, the brain or other parts of the body where leukaemia cells have collected.

Stem Cell Transplant

A stem cell transplant is the replacement of the abnormal bone marrow with stem cells or marrow free of leukaemiafrom a compatible donor.

Before the stem cell transplant, you will receive either chemotherapy or radiation therapy in high dosages. In some cases, even both may be prescribed. This will destroy all your leukaemia cells and normal blood cells in your bone marrow. After which, you will receive the healthy stem cells through a large vein.

The healthy stem cells may come from you or from someone who donates their stem cells to you:

  • From yourself: An autologous stem cell transplant uses your own stem cells. Your stem cells are removed before you get the high-dose chemotherapy or radiation therapy. The cells may then be removed to treat any leukaemia cells present. Your stem cells will be frozen and stored. After you receive treatment to remove leukaemia cells from your marrow, your stem cells will then be thawed and.
  • From a family member or other donor: An allogeneic stem cell transplant uses healthy stem cells from a donor. Your brother, sister, or parent may be the donor. Sometimes the stem cells come from a donor who isn't related. Doctors use blood tests to learn how closely a donor's cells match your cells.
  • From your identical twin: If you have an identical twin, a syngeneic stem cell transplant uses stem cells from your healthy twin. After the transplant, the new blood cells will then develop from the transplanted stem cells and replace those that were destroyed by the treatment. You may have to stay in the hospital for several weeks or months to recuperate. The time needed differs for individuals.



​​​​Our Total Leukaemia Care Approach

Here at the NCIS, we adopt a comprehensive and holistic three-prong Total Leukaemia Care approach in managing patients who have been di​agnosed with Leukaemia.

Under the Total Leukaemia Care approach, emphasis is centred on the patient with clinical, research and educational initiatives focused on them.

We aim to continuously improve on the clinical management of Leukaemia by being involved in research on new treatment. We are also committed to patient education and various ways of support to walk with patients through their journey with Leukaemia.

Optimising Clinical Care

Leukaemia is considered a very heterogenous disease with varying patient survival rates. It is therefore crucial to identify characteristics of patients with different clinical behaviours to administer the suitable treatment process.

At the NCIS, through a risk stratified approach using cytogenetic and molecular testing, we are able provide the appropriate medical care by weighing the both the risks and benefits to give the best treatment outcome.

As part of the the standard Leukaemia treatment, we also offer Bone Marrow Transplantation to patients who would benefit from it. We have an excellent team of transplant physicians who are experienced in both autologous and the various types of allogeneic stem cell transplantations. We have an equally strong team of specialised nurses and allied healthcare professionals support the coordination, counselling and follow-up care of our Leukaemia patients.

Research

Being such a varied disease, much research on continuously being done to improve the treatment outcome and to understand the nature of the disease. This will contribute to the development of new therapeutics in the future. We are also interested in the research on the quality of life and healthcare utilization to obtain a holistic management of Leukaemia here.

We have upcoming clinical trials that gives our patients an opportunity to potentially benefit from new treatment. This includes Phase 1 trials, targeted therapy as well as a cellular therapy in an up-and-coming promising field of immunotherapy.

Patient Education and Support

At the NCIS, we understand that patients afflicted with Leukaemia often feel overwhelmed by the amount and gravity of the information given by the healthcare team, as well as the quick succession of investigations that might need to be done for diagnosis and preparation for treatment.

To provide our patients with a relatable support system to ease them through their journey with the illness, we offer the following support services and functions:

  • A Navigator – To act as a complementary contact point and coordination of medical care.
  • Transplantation Nurse/Advance Practice Nurse – To support the transplantation physician in coordination and counselling of preparation for and long term care after the transplantation.
  • Allied Healthcare Professionals – This includes a medical social worker who provides emotional and financial support to our Leukaemia patients; a dietician who provides personalized advice on nutrition needs; the therapists who provide practical rehabilitation guidance.
  • Patient Support Groups/Befrienders – To embrace patients into a larger support community of like-minded individuals who are there to listen and share their experiences in dealing with the illness.

The Leukaemia Treatment Team at the NCIS is spearheaded by Lead Clinician Dr Ng Chin Hin, and accompanied by his team of medical professionals spanning over multi-disciplinary tumour groups, the team is committed to delivering uncompromised and dedicated clinical research, expertise and care in the prevention, management and cure of Leukaemia.

Haematology-Oncology

Radiation Oncology

Radiology

Pathology